Thomas Jefferson University Researchers Recommend Negative Pressure Therapy Use for Groin Incisions Following Independent Study
New data demonstrates PREVENA™ Incision Management System may reduce reoperation, readmission and hospital costs for high-risk patients.
SAN ANTONIO, June 2, 2017 – New independent data from Thomas Jefferson University in Philadelphia demonstrates the use of negative pressure therapy using PREVENA™ Incision Management System may reduce the rate of major wound complications and associated costs following vascular groin surgery in high-risk patients. The results were presented at the 2017 Society for Vascular Surgery Annual Meeting, held May 31 – June 3 in San Diego.
“There is a risk of complication following any procedure that involves an incision, but the risks are even higher with groin incisions. Morbidity related to groin wounds leads to significant increases in length of stay, need for re-operation, re-admission, and even limb loss,” said Paul DiMuzio, M.D., FACS, lead investigator, Thomas Jefferson University, Philadelphia. “The study results indicate that negative pressure therapy over the closed incision significantly decreases the rates of these complications in patients at high risk, and further reduces associated health care costs well beyond the cost of the therapy.”
Dr. DiMuzio and a team of independent researchers conducted a randomized controlled, prospective, single-institution study at Thomas Jefferson University, evaluating 140 closed femoral incisions treated with the PREVENA™ Incision Management System versus standard gauze dressings, following elective vascular surgery. In the high-risk incision cohort, study results found that the PREVENA™ Incision Management System significantly reduced:
- major wound complications (8.5% PREVENA™ Therapy Group vs. 21.7% Control Group; p<0.001)
- reoperation (8.5% PREVENA™ Therapy Group vs. 18.3% Control Group; p<0.05) and
- readmission (6.8% PREVENA™ Therapy Group vs.16.7% Control Group; p<0.04)
Complications from surgical site infections (SSIs) may lead to reoperation and re-admittance significantly impacting health care costs. SSIs remain a significant burden for patients and the healthcare system, as they are associated with productivity loss, extended hospital stays, increased health care provider visits and greater financial costs.i,ii
“This groundbreaking work adds to the growing body of clinical evidence that clearly demonstrates the use of negative pressure to reduce global health care costs,” said R. Andrew Eckert, President and Chief Executive Officer of Acelity. “The Acelity negative pressure portfolio is the most trusted name in advanced wound therapy having treated more than 10 million wounds around the world. We are thrilled to see our innovative PREVENA™ Therapy provide indisputable benefits to patients, clinicians and health systems.”
Most recently, Acelity launched the PREVENA DUO™ Incision Management System, the first single use negative pressure therapy (NPT) system designed specifically for the simultaneous management of two closed surgical incisions.
The 2017 Vascular Annual Meeting is hosted by the Society for Vascular Surgery® (SVS), a not-for-profit professional medical society with more than 5,600 members, primarily vascular surgeons, who are highly trained to provide patients with all vascular disease treatment options. For more information about SVS and the Annual Meeting, please visit http://vascular.org.
About PREVENA™ Incision Management System
The PREVENA™ System, launched in 2010, is the first disposable negative pressure system designed specifically for the management of closed surgical incisions. The system covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision. Please refer to the Instructions for Use for the PREVENA™ Systems for a complete list of appropriate uses, warnings, and precautions.
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care company that leverages the strengths of Kinetic Concepts, Inc. and Systagenix Wound Management, Limited. Available in more than 90 countries, the innovative and complementary ACELITY™ product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.
i Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-46.
ii Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 2013;57(3):791-5.